InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: ridinbulls post# 26623

Tuesday, 06/18/2019 9:48:22 AM

Tuesday, June 18, 2019 9:48:22 AM

Post# of 34625
Well in the upcoming Q3 2019 there is the initiation of the phase 2 trial for MultiTAA in post-transplant AML, which is the lead product. It's most important because even though its phase 2 solid results or similar results from the phase 1/2 study will yield accelerated approval for this indication.

Then you have updates from the ovarian cancer using TPIV 200 phase 2 study in Q4 of 2019. Then possibly an update for TPIV 200 in breast cancer as well in Q4 2019. Both I believe are interim updates.

Anyone else can chime in if I got something wrong or wants to add to my info.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News